CN116966127B - 一种抗敏修复组合物及其制备方法与应用 - Google Patents
一种抗敏修复组合物及其制备方法与应用 Download PDFInfo
- Publication number
- CN116966127B CN116966127B CN202311071528.3A CN202311071528A CN116966127B CN 116966127 B CN116966127 B CN 116966127B CN 202311071528 A CN202311071528 A CN 202311071528A CN 116966127 B CN116966127 B CN 116966127B
- Authority
- CN
- China
- Prior art keywords
- parts
- skin
- repair composition
- allergic
- fructus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 81
- 230000008439 repair process Effects 0.000 title claims abstract description 52
- 230000003266 anti-allergic effect Effects 0.000 title claims abstract description 49
- 238000002360 preparation method Methods 0.000 title claims description 17
- 239000002994 raw material Substances 0.000 claims abstract description 22
- 235000008282 Sanguisorba officinalis Nutrition 0.000 claims abstract description 16
- 235000008291 Poterium sanguisorba Nutrition 0.000 claims abstract description 14
- 241001313857 Bletilla striata Species 0.000 claims abstract description 13
- 230000001737 promoting effect Effects 0.000 claims abstract description 11
- 244000146462 Centella asiatica Species 0.000 claims abstract description 10
- 235000004032 Centella asiatica Nutrition 0.000 claims abstract description 10
- 239000006187 pill Substances 0.000 claims abstract description 10
- 244000303040 Glycyrrhiza glabra Species 0.000 claims abstract description 9
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 9
- 230000017531 blood circulation Effects 0.000 claims abstract description 9
- 241000218176 Corydalis Species 0.000 claims abstract description 8
- 235000006533 astragalus Nutrition 0.000 claims abstract description 8
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims abstract description 8
- 235000011477 liquorice Nutrition 0.000 claims abstract description 8
- 241000244365 Ligusticum sinense Species 0.000 claims abstract description 7
- 241000045403 Astragalus propinquus Species 0.000 claims abstract description 5
- 240000004064 Poterium sanguisorba Species 0.000 claims abstract 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 34
- 238000003756 stirring Methods 0.000 claims description 24
- 238000000605 extraction Methods 0.000 claims description 23
- 239000000706 filtrate Substances 0.000 claims description 21
- 239000000843 powder Substances 0.000 claims description 20
- 239000000047 product Substances 0.000 claims description 17
- 239000002904 solvent Substances 0.000 claims description 17
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 claims description 16
- 238000010298 pulverizing process Methods 0.000 claims description 12
- 238000010438 heat treatment Methods 0.000 claims description 10
- YPFDHNVEDLHUCE-UHFFFAOYSA-N 1,3-propanediol Substances OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 claims description 9
- 235000019437 butane-1,3-diol Nutrition 0.000 claims description 8
- 239000000463 material Substances 0.000 claims description 8
- 230000001954 sterilising effect Effects 0.000 claims description 8
- DNIAPMSPPWPWGF-VKHMYHEASA-N (+)-propylene glycol Chemical compound C[C@H](O)CO DNIAPMSPPWPWGF-VKHMYHEASA-N 0.000 claims description 7
- 229940035437 1,3-propanediol Drugs 0.000 claims description 7
- 239000006071 cream Substances 0.000 claims description 7
- 229920000166 polytrimethylene carbonate Polymers 0.000 claims description 7
- 238000007873 sieving Methods 0.000 claims description 7
- 238000002791 soaking Methods 0.000 claims description 7
- 238000005303 weighing Methods 0.000 claims description 7
- 239000000499 gel Substances 0.000 claims description 4
- 239000008188 pellet Substances 0.000 claims description 4
- 241001061264 Astragalus Species 0.000 claims description 3
- 240000004534 Scutellaria baicalensis Species 0.000 claims description 3
- 235000017089 Scutellaria baicalensis Nutrition 0.000 claims description 3
- 210000004233 talus Anatomy 0.000 claims description 3
- 241001404789 Smilax glabra Species 0.000 claims description 2
- 238000005057 refrigeration Methods 0.000 claims description 2
- 239000007864 aqueous solution Substances 0.000 claims 1
- 208000003251 Pruritus Diseases 0.000 abstract description 10
- 230000007803 itching Effects 0.000 abstract description 10
- 230000008591 skin barrier function Effects 0.000 abstract description 8
- 206010061218 Inflammation Diseases 0.000 abstract description 7
- 230000004054 inflammatory process Effects 0.000 abstract description 7
- 230000002708 enhancing effect Effects 0.000 abstract description 5
- 230000002401 inhibitory effect Effects 0.000 abstract description 5
- 230000007774 longterm Effects 0.000 abstract description 3
- 210000003205 muscle Anatomy 0.000 abstract description 3
- 230000008961 swelling Effects 0.000 abstract description 3
- 230000007365 immunoregulation Effects 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 70
- 230000000694 effects Effects 0.000 description 22
- 244000173853 Sanguisorba officinalis Species 0.000 description 12
- 235000013399 edible fruits Nutrition 0.000 description 12
- 238000009472 formulation Methods 0.000 description 12
- 239000003795 chemical substances by application Substances 0.000 description 11
- 230000003750 conditioning effect Effects 0.000 description 11
- 238000012360 testing method Methods 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 8
- 241000212948 Cnidium Species 0.000 description 7
- 230000000052 comparative effect Effects 0.000 description 7
- 230000002757 inflammatory effect Effects 0.000 description 7
- 230000037307 sensitive skin Effects 0.000 description 7
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 6
- 241000207929 Scutellaria Species 0.000 description 6
- 240000009022 Smilax rotundifolia Species 0.000 description 6
- 235000003205 Smilax rotundifolia Nutrition 0.000 description 6
- 230000003110 anti-inflammatory effect Effects 0.000 description 6
- 230000004888 barrier function Effects 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 239000003906 humectant Substances 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 241000167550 Centella Species 0.000 description 5
- 206010015150 Erythema Diseases 0.000 description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 5
- 235000018142 Hedysarum alpinum var americanum Nutrition 0.000 description 5
- 240000006461 Hedysarum alpinum var. americanum Species 0.000 description 5
- 206010020751 Hypersensitivity Diseases 0.000 description 5
- 241000212322 Levisticum officinale Species 0.000 description 5
- 244000241872 Lycium chinense Species 0.000 description 5
- 235000015468 Lycium chinense Nutrition 0.000 description 5
- 230000000172 allergic effect Effects 0.000 description 5
- 229940107666 astragalus root Drugs 0.000 description 5
- 208000010668 atopic eczema Diseases 0.000 description 5
- 239000001645 levisticum officinale Substances 0.000 description 5
- 230000003020 moisturizing effect Effects 0.000 description 5
- 238000005086 pumping Methods 0.000 description 5
- 229910001220 stainless steel Inorganic materials 0.000 description 5
- 239000010935 stainless steel Substances 0.000 description 5
- 230000008859 change Effects 0.000 description 4
- 230000001815 facial effect Effects 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- 230000007794 irritation Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 206010016807 Fluid retention Diseases 0.000 description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 3
- 241000112528 Ligusticum striatum Species 0.000 description 3
- 206010070834 Sensitisation Diseases 0.000 description 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 3
- 206010040844 Skin exfoliation Diseases 0.000 description 3
- 208000026935 allergic disease Diseases 0.000 description 3
- 230000007815 allergy Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000002354 daily effect Effects 0.000 description 3
- 210000004207 dermis Anatomy 0.000 description 3
- 230000035618 desquamation Effects 0.000 description 3
- 238000011010 flushing procedure Methods 0.000 description 3
- 229960001340 histamine Drugs 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 230000008929 regeneration Effects 0.000 description 3
- 238000011069 regeneration method Methods 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 210000000434 stratum corneum Anatomy 0.000 description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- TXFPEBPIARQUIG-UHFFFAOYSA-N 4'-hydroxyacetophenone Chemical compound CC(=O)C1=CC=C(O)C=C1 TXFPEBPIARQUIG-UHFFFAOYSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- 241001313855 Bletilla Species 0.000 description 2
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 108090001007 Interleukin-8 Proteins 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 2
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 244000046052 Phaseolus vulgaris Species 0.000 description 2
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 108060008539 Transglutaminase Proteins 0.000 description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 2
- 230000001760 anti-analgesic effect Effects 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 229960003237 betaine Drugs 0.000 description 2
- 229960001631 carbomer Drugs 0.000 description 2
- 229940106189 ceramide Drugs 0.000 description 2
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 239000003974 emollient agent Substances 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 229960000367 inositol Drugs 0.000 description 2
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 2
- WCVRQHFDJLLWFE-UHFFFAOYSA-N pentane-1,2-diol Chemical compound CCCC(O)CO WCVRQHFDJLLWFE-UHFFFAOYSA-N 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 150000005856 steroid saponins Chemical class 0.000 description 2
- 102000003601 transglutaminase Human genes 0.000 description 2
- 229930182493 triterpene saponin Natural products 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- NZGWDASTMWDZIW-MRVPVSSYSA-N (+)-pulegone Chemical compound C[C@@H]1CCC(=C(C)C)C(=O)C1 NZGWDASTMWDZIW-MRVPVSSYSA-N 0.000 description 1
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- FXNFHKRTJBSTCS-UHFFFAOYSA-N Baicalein Natural products C=1C(=O)C=2C(O)=C(O)C(O)=CC=2OC=1C1=CC=CC=C1 FXNFHKRTJBSTCS-UHFFFAOYSA-N 0.000 description 1
- 244000301850 Cupressus sempervirens Species 0.000 description 1
- 229920000832 Cutin Polymers 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 206010063560 Excessive granulation tissue Diseases 0.000 description 1
- 235000017443 Hedysarum boreale Nutrition 0.000 description 1
- 235000007858 Hedysarum occidentale Nutrition 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 102000004125 Interleukin-1alpha Human genes 0.000 description 1
- 108010082786 Interleukin-1alpha Proteins 0.000 description 1
- 102000004890 Interleukin-8 Human genes 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- IPQKDIRUZHOIOM-UHFFFAOYSA-N Oroxin A Natural products OC1C(O)C(O)C(CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IPQKDIRUZHOIOM-UHFFFAOYSA-N 0.000 description 1
- HPUXDMUGCAWDFW-UHFFFAOYSA-N Osthole Natural products COc1ccc2CCC(=O)Oc2c1C=CC(=O)C HPUXDMUGCAWDFW-UHFFFAOYSA-N 0.000 description 1
- YKRGDOXKVOZESV-WRJNSLSBSA-N Paeoniflorin Chemical compound C([C@]12[C@H]3O[C@]4(O)C[C@](O3)([C@]1(C[C@@H]42)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C)OC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-WRJNSLSBSA-N 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 1
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 1
- NZGWDASTMWDZIW-UHFFFAOYSA-N Pulegone Natural products CC1CCC(=C(C)C)C(=O)C1 NZGWDASTMWDZIW-UHFFFAOYSA-N 0.000 description 1
- 244000007853 Sarothamnus scoparius Species 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 208000028990 Skin injury Diseases 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 206010040914 Skin reaction Diseases 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 208000002847 Surgical Wound Diseases 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 102000003563 TRPV Human genes 0.000 description 1
- 108060008564 TRPV Proteins 0.000 description 1
- 102000003566 TRPV1 Human genes 0.000 description 1
- 101150016206 Trpv1 gene Proteins 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- USMNOWBWPHYOEA-UHFFFAOYSA-N alpha-thujone Natural products CC1C(=O)CC2(C(C)C)C1C2 USMNOWBWPHYOEA-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 235000019206 astragalus extract Nutrition 0.000 description 1
- UDFLTIRFTXWNJO-UHFFFAOYSA-N baicalein Chemical compound O1C2=CC(=O)C(O)=C(O)C2=C(O)C=C1C1=CC=CC=C1 UDFLTIRFTXWNJO-UHFFFAOYSA-N 0.000 description 1
- 229940015301 baicalein Drugs 0.000 description 1
- IKIIZLYTISPENI-ZFORQUDYSA-N baicalin Chemical compound O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IKIIZLYTISPENI-ZFORQUDYSA-N 0.000 description 1
- 229960003321 baicalin Drugs 0.000 description 1
- AQHDANHUMGXSJZ-UHFFFAOYSA-N baicalin Natural products OC1C(O)C(C(O)CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 AQHDANHUMGXSJZ-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229940076810 beta sitosterol Drugs 0.000 description 1
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 1
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- ILMMCBFQWHPTHE-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O.CCCC(O)O ILMMCBFQWHPTHE-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 230000037319 collagen production Effects 0.000 description 1
- 238000005056 compaction Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 description 1
- 210000001126 granulation tissue Anatomy 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- ACCCMOQWYVYDOT-UHFFFAOYSA-N hexane-1,1-diol Chemical compound CCCCCC(O)O ACCCMOQWYVYDOT-UHFFFAOYSA-N 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 229960004873 levomenthol Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- MBRLOUHOWLUMFF-UHFFFAOYSA-N osthole Chemical compound C1=CC(=O)OC2=C(CC=C(C)C)C(OC)=CC=C21 MBRLOUHOWLUMFF-UHFFFAOYSA-N 0.000 description 1
- 229930007459 p-menth-8-en-3-one Natural products 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- YKRGDOXKVOZESV-UHFFFAOYSA-N paeoniflorin Natural products O1C(C)(C2(CC34)OC5C(C(O)C(O)C(CO)O5)O)CC3(O)OC1C24COC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-UHFFFAOYSA-N 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000037368 penetrate the skin Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000008832 photodamage Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 238000010517 secondary reaction Methods 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 229950005143 sitosterol Drugs 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 230000037394 skin elasticity Effects 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 231100000245 skin permeability Toxicity 0.000 description 1
- 230000035483 skin reaction Effects 0.000 description 1
- 231100000430 skin reaction Toxicity 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- -1 steroid compounds Chemical class 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 150000008130 triterpenoid saponins Chemical class 0.000 description 1
- 229940096998 ursolic acid Drugs 0.000 description 1
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/005—Preparations for sensitive skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
- A61K2800/782—Enzyme inhibitors; Enzyme antagonists
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/82—Preparation or application process involves sonication or ultrasonication
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Birds (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明涉及一种抗敏修复组合物,包括以下重量份原料:黄芪10‑20份、黄芩5‑15份、地榆12‑18份、白芨12‑18份、积雪草10‑20份、甘草10‑20份、川穹5‑15份、土茯苓5‑15份、活血丹10‑20份、延胡索10‑25份、地肤子6‑18份、蛇床子5‑20份。本发明针对敏感肌的病理特点出发,从修复皮肤屏障、增强肌肤免疫调节、抑制炎症反应、修复受损细胞作用等方面辩证配伍,使得组合物能够在短时间内缓解红肿、瘙痒,长期使用又能够有效地对皮肤角质层进行修护。
Description
技术领域
本发明涉及护肤品技术领域,更具体地说,它涉及一种抗敏修复组合物及其制备方法与应用。
背景技术
近年来受敏感肌困扰的人越来越多,有流行病学研究表明,女性敏感皮肤的患病率60-70%,男性占50-60%。敏感皮肤是指表现出高反应性和低耐受性的皮肤,通常认为是一种亚稳状态的皮肤。
敏感的皮肤主要发生在面部,特点是质地干燥、收缩和红斑,没有皮肤病变或疾病。此外,即使是轻微的刺激也会导致瘙痒、脱屑、灼烧或刺痛的感觉。由于敏感皮肤的病因和发病机制复杂,目前还没有针对敏感皮肤的有效治疗方法。因此,使用有针对性的化妆品和注意日常皮肤护理对缓解敏感皮肤的症状具有重要作用。
CN113018222A公开了一种针对敏感肌肌肤屏障修复的多效霜,包括A组制剂,B组制剂,C组制剂,D组制剂,E组制剂,F组制剂,G组制剂,H组制剂。该多效霜具有即时舒敏、修复屏障、镇静、保湿和抗氧化多效合一,通过调节细胞因子来抑制炎症的初级反应抑制IL-1α、TNF-α来阻止反应抑制IL-6、IL-8从源头减少泛红,通过调节脂质介质来抑制炎症的次级反应抑制COX-2、PGE-2防止泛红、红斑,在不降低肌肤角质屏障的防御能力下,使用后肌肤更柔软。
上述专利仅从抑制炎症角度来减轻过敏症状,未着手修复角质屏障,只能在短时间内抗敏止痒,并不能对肌肤进行深层修护,治标不治本。
发明内容
针对现有技术存在的不足,本发明的目的在于提供一种抗敏修复组合物,该组合物能够在短时间内缓解红肿、瘙痒,长期使用又能够有效地对皮肤角质层进行修护。
为实现上述目的,本发明提供了一种抗敏修复组合物,包括以下重量份原料:黄芪10-20份、黄芩5-15份、地榆12-18份、白芨12-18份、积雪草10-20份、甘草10-20份、川穹5-15份、土茯苓5-15份、活血丹10-20份、延胡索10-25份、地肤子6-18份、蛇床子5-20份。
优选地,包括以下重量份原料:黄芪13-18份、黄芩10-15份、地榆15-18份、白芨12-16份、积雪草13-18份、甘草15-20份、川穹10-15份、土茯苓10-15份、活血丹13-18份、延胡索15-22份、地肤子6-12份、蛇床子12-18份。
优选地,包括以下重量份原料:黄芪15份、黄芩8份、地榆15份、白芨15份、积雪草15份、甘草15份、川穹10份、土茯苓10份、活血丹15份、延胡索15份、地肤子10份、蛇床子15份。
组合物中各原料的药理作用如下:
黄芪:其提取物能消除皮肤中的游离基,也起着抗氧化、舒缓抗敏的功效。
黄芩:其根提取物中的黄芩素、黄芩苷能够拮抗组胺,通过抑制炎症反应来减轻过敏症状;同时具有一定的抗氧化、杀菌功效。
地榆:地榆为外科创面修复的常用药,具有止血、抑制炎性介质、抗菌消肿、增强免疫功能、抗氧化的作用;可以促进上皮组织生长、肉芽组织增生及胶原蛋白的生成,从而起到修复角质层、增强皮肤屏障、提高真皮层保水锁水的功效。
白芨:其提取物可抑制TRPV1,减少刺激,与黄芩合用进一步降低释放组胺、TNF-α、IL-1、IL-8。
积雪草:其提取物有较好的修复疤痕、消炎的功效;与地榆合用能进一步促进伤口愈合和皮肤损伤,促进皮肤胶原蛋白再生,增强细胞基底层细胞活力,保持肌肤弹性及紧实,进一步提高产品的修复效果。
甘草:其提取物能降低转谷酰胺酶CK-17表达、降低转谷酰胺酶Tgase表达,能够修复因UVB损伤的屏障功能,对防护皮肤光损伤有确切疗效。
川芎:其根提取物能促进神经酰胺合成,而神经酰胺具有优异的保湿功效,通过增加皮肤含水量,维持角质层的水合作用而起到屏障修护功效。
土茯苓:其提取物能抑制NF-KB,抑制IL-6,通过抑制炎症反应来减轻过敏症状。
活血丹:其提取物含有丰富的熊果酸、左旋薄荷酮、胡薄荷酮、β谷甾醇、琥珀酸、多种氨基酸以及维生素C,能够抑制炎症介质的传递,有效抑制组胺的释放和抑制TRPV1表达。
延胡索:其提取物具有镇静抗炎功效,并能提高机体免疫力。
地肤子:其提取物含有具有清热利湿和祛风止痒的三萜皂苷、维生素A;同时由于三萜皂苷、甾体皂苷和芍药苷具有良好的皮肤穿透性,能增加皮肤的透过性,进而使得其它活性成分也能穿透皮肤,能够顺利的被皮肤吸收,提高抗敏修护组合物的皮肤吸收率。有多种醇、有机酸、三萜皂苷及甾类化合物等。另外,甾体皂苷可有效抑制多种微生物于皮肤表面繁殖,并抑制微生物分泌物以及损伤细胞分泌物诱导的炎症递质释放,还能降低炎症因子的基因表达,减少相关炎症因子释放,进而能减少甚至防止炎症和其他变态反应的发生,从而达到预防过敏与皮肤炎症的效果。
蛇床子:其提取物中的蛇床子素通过调节免疫系统的功能来减轻过敏反应。另外,吸湿试验表明其具有很好的吸湿性和保湿性,对皮肤有护理作用。
本发明的第二目的在于提供一种抗敏修复组合物的制备方法,具有制备简单、操作方便的优点,其包括以下步骤:
(1)将各原料准确称量后,粉碎机打粉,筛分细度20-40目,得药粉;
(2)配制由1,3-丙二醇、1,3-丁二醇和纯水组成的提取溶剂,搅匀备用;
(3)将药粉与提取溶剂按重量比为1:(5-10)的比例加入提取罐中,搅拌均匀后浸泡100-150min,得混合物料;
(4)将混合物料加热保温至50-60℃,开启搅拌,超声提取30-45min,首次离心除去药渣,收集一级滤液;
(5)将滤液冷藏24H,再次离心除去药渣,收集二级滤液,灭菌处理后即得所述抗敏修复组合物。
优选地,步骤(2)中的提取溶剂由1,3-丙二醇、1,3-丁二醇、纯水按15:15:70的重量比组成。
优选地,步骤(5)中的冷藏温度为5-8℃。
本发明的第三目的在于提供一种抗敏修复组合物的应用,具体为将上述抗敏修复组合物添加到护肤品中,其中护肤品的剂型为水剂、粉剂、膏霜、啫喱中的任一种,具有适用范围广泛的优点。
本申请具有以下有益效果:
(1)各组分经辨证配伍,黄芩、白芨、甘草、土茯苓、活血丹复配用于通过抑制多种炎症介质的释放和调节免疫系统来减轻过敏症状,能够有提高消炎、镇痛效果,提升皮肤的自我保护能力,有效修护炎症肌肤,特别是患有激素性依赖皮炎的肌肤,且长期使用不会产生耐药性、依赖性和副作用;利用地榆、积雪草促进上皮组织生长、伤口愈合及胶原蛋白再生,增强细胞基底层细胞活力从而起到修复角质层、增强皮肤屏障、提高真皮层保水锁水的功效;利用黄芪的抗氧化能力促进受损细胞的修复和再生,从而起到长效的抗敏效果;利用川芎、蛇床子的保湿锁水功效巩固皮肤屏障的功能,防止皮肤水分过度流失;利用地肤子提高皮肤的通透性,与其他活性组分相互复配后,使其快速的直达病灶,发挥持久药效作用;使得到的护肤组合物具有良好的修护效果,既能够在短时间内止痒、褪红,又能修护皮肤角质层,增强皮肤屏障,强化细胞保湿修护功能。
(2)选择低刺激性的植物作为主要抗敏修护原料,采用超声波加热的萃取方法,高效地淬炼出植物的活性成分。
(3)将抗敏修复组合物添加到护肤品中,有利于提高护肤品的抗敏修护效果,有利于抗敏修复组合物的广泛应用。
具体实施方式
下面结合实施例对本发明作进一步的描述,但本发明要求保护的范围并不局限于实施例表述的范围。
实施例1
一种抗敏修复组合物,包括以下原料:黄芪根10g、黄芩根5g、地榆根12g、白芨根12g、积雪草10g、甘草根10g、川穹根5g、土茯苓根5g、活血丹10g、延胡索根10g、地肤子6g、蛇床子5g。
上述抗敏修复组合物的制备方法,包括步骤如下:
(1)将各原料准确称量后,粉碎机打粉,筛分细度40目,筛余物继续粉碎至全过筛,得药粉;
(2)按15:15:70的重量比配制由1,3-丙二醇、1,3-丁二醇和纯水组成的提取溶剂,搅匀备用;
(3)将药粉与提取溶剂按重量比为1:10的比例加入提取罐中,搅拌均匀后浸泡150min,得混合物料;
(4)将混合物料加热保温至60℃,开启搅拌,以28KHZ、1200W的参数超声提取45min,首次离心除去药渣,收集一级滤液;
(5)将滤液在5-8℃下冷藏24H,再次离心除去药渣,收集二级滤液,抽入夹套不锈钢锅中,水浴恒温至90℃±2℃,进行灭菌30min,即得一种抗敏修复组合物。
实施例2
一种抗敏修复组合物,包括以下原料:黄芪根20g、黄芩根15g、地榆根18g、白芨根18g、积雪草20g、甘草根20g、川穹根15g、土茯苓根15g、活血丹20g、延胡索根25g、地肤子18g、蛇床子20g。
上述抗敏修复组合物的制备方法,包括步骤如下:
(1)将各原料准确称量后,粉碎机打粉,筛分细度20目,筛余物继续粉碎至全过筛,得药粉;
(2)按15:15:70的重量比配制由1,3-丙二醇、1,3-丁二醇和纯水组成的提取溶剂,搅匀备用;
(3)将药粉与提取溶剂按重量比为1:5的比例加入提取罐中,搅拌均匀后浸泡100min,得混合物料;
(4)将混合物料加热保温至50℃,开启搅拌,以28KHZ、1200W的参数超声提取30min,首次离心除去药渣,收集一级滤液;
(5)将滤液在5-8℃下冷藏24H,再次离心除去药渣,收集二级滤液,抽入夹套不锈钢锅中,水浴恒温至90℃±2℃,进行灭菌30min,即得一种抗敏修复组合物。
实施例3
一种抗敏修复组合物,包括以下原料:黄芪根15g、黄芩根8g、地榆根15g、白芨根15g、积雪草15g、甘草根15g、川穹根10g、土茯苓根10g、活血丹15g、延胡索根15g、地肤子10g、蛇床子15g。
上述抗敏修复组合物的制备方法,包括步骤如下:
(1)将各原料准确称量后,粉碎机打粉,筛分细度30目,筛余物继续粉碎至全过筛,得药粉;
(2)按15:15:70的重量比配制由1,3-丙二醇、1,3-丁二醇和纯水组成的提取溶剂,搅匀备用;
(3)将药粉与提取溶剂按重量比为1:10的比例加入提取罐中,搅拌均匀后浸泡120min,得混合物料;
(4)将混合物料加热保温至50℃,开启搅拌,以28KHZ、1200W的参数超声提取30min,首次离心除去药渣,收集一级滤液;
(5)将滤液在5-8℃下冷藏24H,再次离心除去药渣,收集二级滤液,抽入夹套不锈钢锅中,水浴恒温至90℃±2℃,进行灭菌30min,即得一种抗敏修复组合物。
实施例4
一种抗敏修复组合物,包括以下原料:黄芪根18g、黄芩根13g、地榆根18g、白芨根12g、积雪草18g、甘草根15g、川穹根15g、土茯苓根10g、活血丹13g、延胡索根22g、地肤子12g、蛇床子18g。
上述抗敏修复组合物的制备方法,包括步骤如下:
(1)将各原料准确称量后,粉碎机打粉,筛分细度30目,筛余物继续粉碎至全过筛,得药粉;
(2)按15:15:70的重量比配制由1,3-丙二醇、1,3-丁二醇和纯水组成的提取溶剂,搅匀备用;
(3)将药粉与提取溶剂按重量比为1:8的比例加入提取罐中,搅拌均匀后浸泡120min,得混合物料;
(4)将混合物料加热保温至55℃,开启搅拌,以28KHZ、1200W的参数超声提取35min,首次离心除去药渣,收集一级滤液;
(5)将滤液在5-8℃下冷藏24H,再次离心除去药渣,收集二级滤液,抽入夹套不锈钢锅中,水浴恒温至90℃±2℃,进行灭菌30min,即得一种抗敏修复组合物。
实施例5
一种抗敏修复组合物,包括以下原料:黄芪根13g、黄芩根10g、地榆根15g、白芨根16g、积雪草13g、甘草根20g、川穹根10g、土茯苓根15g、活血丹18g、延胡索根15g、地肤子6g、蛇床子12g。
上述抗敏修复组合物的制备方法,包括步骤如下:
(1)将各原料准确称量后,粉碎机打粉,筛分细度30目,筛余物继续粉碎至全过筛,得药粉;
(2)按15:15:70的重量比配制由1,3-丙二醇、1,3-丁二醇和纯水组成的提取溶剂,搅匀备用;
(3)将药粉与提取溶剂按重量比为1:8的比例加入提取罐中,搅拌均匀后浸泡120min,得混合物料;
(4)将混合物料加热保温至50℃,开启搅拌,以28KHZ、1200W的参数超声提取35min,首次离心除去药渣,收集一级滤液;
(5)将滤液在5-8℃下冷藏24H,再次离心除去药渣,收集二级滤液,抽入夹套不锈钢锅中,水浴恒温至90℃±2℃,进行灭菌30min,即得一种抗敏修复组合物。
对比例1
一种抗敏修复组合物,其原料组成与实施例3对比,地榆根为30g、白芨积雪草为0g,其制备方法与实施例3相同。
对比例2
一种抗敏修复组合物,其原料组成与实施例3对比,地榆根为0g、积雪草为30g,其制备方法与实施例3相同。
对比例3
一种抗敏修复组合物,其原料组成与实施例3对比,地肤子6g,其制备方法与实施例3相同。
对比例4
一种抗敏修复组合物,其原料组成与实施例3对比,地肤子2g,其制备方法与实施例3相同。
将实施例1-5及对比例1-4得到的抗敏修护组合物按表1配方分别制备成一种精华水(依次对应为产品1、产品2、产品3·····产品9),用于功效评价。
表1精华水配方表
功效评价
为表明本发明的抗敏修复组合物具有良好的修护效果,将实施例1-5及对比例1-4制备得到精华水进行以下测试。
挑选180名年龄在20-45周岁之间的试用人员,按其皮肤敏感程度由弱到强的顺序分为三种皮肤类型,其中36人在日常皮肤护理过程中偶尔会出现面部轻微瘙痒、潮红、干燥等现象,为I型皮肤;其中90人在日常皮肤护理过程中会经常出现面部瘙痒、潮红、干燥、脱屑等现象,为II型皮肤;其中54人已出现严重的面部瘙痒、潮红、干燥、疼痛、脱屑等症状,为III型皮肤。将上述每种敏感皮肤类型的人员平均分为9组,每组20人分别试用产品1-9,连续2周,早晚各使用一次。
用visia测试试用人员脸部皮肤的红区变化情况,用CK测试试用人员脸部皮肤经皮失水流失变化情况和皮肤的总水分含量变化情况,来得出修复皮肤效果。
测试条件:(1)室内环境;(2)无强烈阳光或灯光直射;(3)环境温度20±2℃,环境湿度40-60%。测试区域:全脸。测试步骤:先测量被测试区域清洁后30min的空白值(红区面积、经皮水分流失、皮肤含水量),然后规定试用人员每天早晚坚持使用对应的产品,2周后分别测试区域内的红区面积,经皮失水流失情况,皮肤的含水量。
疗效判断标准:
痊愈:皮肤红区面积减少超过80%;经皮水分流失减少超过20%,皮肤含水量增加超过40%;
显效:皮肤红区面积减少超过50%;经皮水分流失减少超过10%,皮肤含水量增加超过30%;
有效:皮肤红区面积减少超过20%;经皮水分流失减少超过10%,皮肤含水量增加不足20%;
无效:皮肤红区面积减少不足20%;经皮水分流失减少超过10%,皮肤含水量增加不足10%。
结果如表2所示:
表2各精华水的抗敏修复测试数据
从表2可以看出:本发明的敏感修复组合物应用到护肤品中能获得良好的修护效果,既能够在短时间内止痒、褪红,又能修护皮肤角质层,增强皮肤屏障,强化细胞保湿修护功能;黄芩、白芨等抗炎组分复配后能减轻过敏症状,能够有提高消炎、镇痛效果,提升皮肤的自我保护能力;地榆与积雪草能增强皮肤屏障、提高真皮层及角质层的保湿锁水功效,川芎与蛇床子进一步地巩固皮肤屏障的功能,防止皮肤水分过度流失;地肤子在发挥抗炎、抗菌功效外,还能提高皮肤的通透性,与其他活性组分相互复配后,使其快速的直达病灶,发挥持久药效作用。
为了测试本发明的抗敏修复组合物刺激性强弱,将实施例1-5及对比例4制备得到的抗敏修复组合物做斑点贴敷实验,分别取等量样品贴敷于受试者的手臂曲侧,用手掌轻压使之均匀的贴敷于皮肤上,并进行30分钟,4小时,24小时观察,观察肌肤刺激性变化,按表3的标准进行评分,结果如下表4所示:
表3斑点贴敷皮肤反应分级标准表
表4各反应等级人数表
上述结果显示:本发明制备得到的抗敏修复组合物均无不良反应,刺激性低、安全性高。
为了丰富本发明组合物的应用范围,可将组合物制备成本领域常见的护肤品剂型,如表5-7所示的啫喱、膏霜、冻干粉等。
表5啫喱配方表
序号 | 组分 | 重量百分比 | 使用目的 |
1 | 水 | 60.85 | 溶剂 |
2 | 抗敏修复组合物 | 20 | 皮肤调理剂 |
3 | 卡波姆 | 0.6 | 增稠剂 |
4 | 甘油 | 6 | 保湿剂 |
5 | 丁二醇 | 6 | 保湿剂 |
6 | 甜菜碱 | 2 | 保湿剂 |
7 | 透明质酸钠 | 0.2 | 保湿剂 |
8 | 烟酰胺 | 2 | 皮肤调理剂 |
9 | 肌醇 | 1 | 皮肤调理剂 |
10 | 对羟基苯乙酮 | 0.4 | 皮肤调理剂 |
11 | 己二醇 | 0.7 | 保湿剂 |
12 | 尿囊素 | 0.15 | 皮肤调理剂 |
13 | EDTA二钠 | 0.1 | 螯合剂 |
表6膏霜配方表
表7冻干粉配方表
序号 | 组分 | 重量百分比 | 使用目的 |
1 | 水 | 69.6 | 溶剂 |
2 | 抗敏修复组合物 | 8.6 | 皮肤调理剂 |
3 | 甘露糖醇 | 6 | 保湿剂 |
4 | 甘油 | 1.2 | 润肤剂 |
5 | 甘氨酸 | 1.2 | 皮肤调理剂 |
6 | 亮氨酸 | 0.5 | 皮肤调理剂 |
7 | 丝氨酸 | 1.6 | 皮肤调理剂 |
8 | 海藻糖 | 5.6 | 皮肤调理剂 |
9 | 酸豆籽多糖 | 3.2 | 皮肤调理剂 |
10 | 1,2-戊二醇 | 2.5 | 润肤剂 |
上述冻干粉由如下步骤制得:
(1)将水、甘油、甘氨酸、亮氨酸、丝氨酸、海藻糖、酸豆籽多糖混合,加热至40℃,保温50min,搅拌均匀,得混合物A;
(2)将甘露糖醇、抗敏修复组合物、1,2-戊二醇混合,搅拌均匀,得混合物B;
(3)将混合物A降温至5℃,然后加入混合物B中,慢速搅拌2h,得混合物C;
(4)将混合液C置于容器中低温冻干,具体方法为:先在-45℃下预冷冻5h,然后在-35℃下抽真空至1Pa;再进行梯度升温至30℃,并控制温度变化梯度每次为5℃,每温度梯度的冻干时间2h,使得容器中的混合液C冻干至呈现为冻干粉的形式,再在真空状态下压塞,轧盖,包装,得一种具有抗菌祛痘功效的冻干粉。
以上所述仅是本发明的优选实施方式,本发明的保护范围并不仅局限于上述实施例,凡属于本发明思路下的技术方案均属于本发明的保护范围。应当指出,对于本技术领域的普通技术人员来说,在不脱离本发明原料前提下的若干改进和润饰,这些改进和润饰也应视为本发明的保护范围。
Claims (6)
1.一种抗敏修复组合物,其特征在于,由以下步骤制得:
(1)依次称取黄芪10-20份、黄芩5-15份、地榆12-18份、白芨12-18份、积雪草10-20份、甘草10-20份、川穹5-15份、土茯苓5-15份、活血丹10-20份、延胡索10-25份、地肤子6-18份、蛇床子5-20份;然后将上述原料用粉碎机打粉,筛分细度20-40目,得药粉;
(2)按1,3-丙二醇:1,3-丁二醇:纯水=15:15:70的重量比配制提取溶剂,搅匀备用;
(3)将药粉与提取溶剂按重量比为1:(5-10)的比例加入提取罐中,搅拌均匀后浸泡100-150min,得混合物料;
(4)将混合物料加热保温至50-60℃,开启搅拌,超声提取30-45min,首次离心除去药渣,收集一级滤液;
(5)将滤液冷藏24H,再次离心除去药渣,收集二级滤液,灭菌处理后即得所述抗敏修复组合物。
2.根据权利要求1所述抗敏修复组合物,其特征在于,由以下重量份原料制得:黄芪13-18份、黄芩10-15份、地榆15-18份、白芨12-16份、积雪草13-18份、甘草15-20份、川穹10-15份、土茯苓10-15份、活血丹13-18份、延胡索15-22份、地肤子6-12份、蛇床子12-18份。
3.根据权利要求1所述抗敏修复组合物,其特征在于,由以下重量份原料制得:黄芪15份、黄芩8份、地榆15份、白芨15份、积雪草15份、甘草15份、川穹10份、土茯苓10份、活血丹15份、延胡索15份、地肤子10份、蛇床子15份。
4.根据权利要求1所述抗敏修复组合物,其特征在于,步骤(5)中的冷藏温度为5-8℃。
5.如权利要求1-3任一项所述抗敏修复组合物在制备护肤品中的应用。
6.根据权利要求5所述抗敏修复组合物的应用,其特征在于,所述护肤品的剂型为水剂、粉剂、膏霜、啫喱中的任一种。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311071528.3A CN116966127B (zh) | 2023-08-24 | 2023-08-24 | 一种抗敏修复组合物及其制备方法与应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311071528.3A CN116966127B (zh) | 2023-08-24 | 2023-08-24 | 一种抗敏修复组合物及其制备方法与应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN116966127A CN116966127A (zh) | 2023-10-31 |
CN116966127B true CN116966127B (zh) | 2024-02-13 |
Family
ID=88485091
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202311071528.3A Active CN116966127B (zh) | 2023-08-24 | 2023-08-24 | 一种抗敏修复组合物及其制备方法与应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116966127B (zh) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104127331A (zh) * | 2014-08-07 | 2014-11-05 | 广东一方制药有限公司 | 一种提高皮肤抗敏及修复能力的护肤品及其制备方法 |
CN106726965A (zh) * | 2016-12-26 | 2017-05-31 | 湖南御家化妆品制造有限公司 | 抗敏舒缓的护肤品组合物及其制备方法 |
CN114931530A (zh) * | 2022-03-22 | 2022-08-23 | 广东丸美生物技术股份有限公司 | 一种具有抗敏和修复作用的护肤组合物及其应用和化妆品及其方法 |
CN115105425A (zh) * | 2022-08-11 | 2022-09-27 | 羽楠(广州)化妆品有限公司 | 一种敏感肌肤修复组合物及其应用 |
-
2023
- 2023-08-24 CN CN202311071528.3A patent/CN116966127B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104127331A (zh) * | 2014-08-07 | 2014-11-05 | 广东一方制药有限公司 | 一种提高皮肤抗敏及修复能力的护肤品及其制备方法 |
CN106726965A (zh) * | 2016-12-26 | 2017-05-31 | 湖南御家化妆品制造有限公司 | 抗敏舒缓的护肤品组合物及其制备方法 |
CN114931530A (zh) * | 2022-03-22 | 2022-08-23 | 广东丸美生物技术股份有限公司 | 一种具有抗敏和修复作用的护肤组合物及其应用和化妆品及其方法 |
CN115105425A (zh) * | 2022-08-11 | 2022-09-27 | 羽楠(广州)化妆品有限公司 | 一种敏感肌肤修复组合物及其应用 |
Non-Patent Citations (3)
Title |
---|
"中医皮肤病方药研究";喻文球;《江西中医学院学报》;第第13卷卷(第第3期期);138-139 * |
"化妆品中常用中草药原料研究进展";谢艳君等;《中国中药杂志》;第第40卷卷(第第20期期);3925-3931 * |
"化妆品植物资源的开发与利用";黄清俊;《江西林业科技》(第第2期期);24-28 * |
Also Published As
Publication number | Publication date |
---|---|
CN116966127A (zh) | 2023-10-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107550775B (zh) | 天然植物祛痘啫喱及其制备方法 | |
CN106420505B (zh) | 一种中药植物组合物、其制备方法及应用 | |
CN111228207B (zh) | 祛湿疹护臀霜及其制备方法 | |
CN113368018A (zh) | 抗炎祛痘组合物及其制备方法 | |
CN110840768B (zh) | 一种艾草精华原液及其制备方法 | |
CN115025024A (zh) | 一种祛痘消印组合物及其应用 | |
CN116850122A (zh) | 一种抗菌祛痘组合物及其制备方法与应用 | |
CN116966127B (zh) | 一种抗敏修复组合物及其制备方法与应用 | |
CN111821230A (zh) | 一种防敏修复的化妆品组合物及其应用 | |
CN112755143B (zh) | 一种治疗湿疹的中药组合物及其应用 | |
CN108938511A (zh) | 天然植物提取物的组合物及在皮肤保湿祛痘产品中的应用 | |
CN109568181B (zh) | 一种茶油护手霜 | |
CN110151657B (zh) | 一种含有垂盆草提取物的祛痘凝胶及其制备方法 | |
CN109431881B (zh) | 一种防皮肤干裂的藏绵羊油 | |
CN103920124B (zh) | 一种杀菌护肤冻疮膏 | |
CN113491664A (zh) | 一种用于快速缓解瘙痒的组合物及其制备方法与用途 | |
CN112870140A (zh) | 一种抗敏止痒组合物、护肤凝露及其制备方法、应用 | |
CN107714585B (zh) | 含有积雪草提取物的保湿霜 | |
CN111467456A (zh) | 一种治疗颈椎腰腿疼痛的膏药 | |
CN111588670A (zh) | 一种三七面霜及其制备方法 | |
CN112107523A (zh) | 清润祛痘组合物以及清润祛痘面膜 | |
CN112656706A (zh) | 一种化妆品修复原液及其制作方法 | |
CN108379374A (zh) | 一种用于治疗冻疮的药膏及其制备方法 | |
CN110840805B (zh) | 一种祛痘组合物及化妆品 | |
CN115634244B (zh) | 一种治疗湿疹的中药组合物、制备方法及其制剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |